AIM: To study the clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. METHODS: To investigate the expression of p53 and mdm2 in pancreatic cancer by immunohistochemistry, and the relationships between the p53 and mdm2 protein expression and clinicopathological parameters in pancreatic cancer. RESULTS: The positive expression of p53 protein was found in 40 of 59 patients (67.8%) and that of mdm2 protein in 17 of 59 patients (28.8%). No obvious relationships were found between p53 as well as mdm2 expression and sex, tumor site, TNM staging and histological differentiation. p53 expression was increased in patients younger than 65 years old, while mdm2 had no relationship with age. The survival time of the patients with the positive expression of p53 and mdm2 proteins was obviously shorter than the other groups. CONCLUSION: Both p53 and mdm2 presented relatively high expression in human pancreatic cancer. The overexpression of p53 and mdm2 might reflect the malignant proliferation of pancreatic cancer and their co-expression might be helpful to evaluate the prognosis of the patients with pancreatic cancer.
AIM: To study the clinicopathological significance of p53 and mdm2 protein expression in humanpancreatic cancer. METHODS: To investigate the expression of p53 and mdm2 in pancreatic cancer by immunohistochemistry, and the relationships between the p53 and mdm2 protein expression and clinicopathological parameters in pancreatic cancer. RESULTS: The positive expression of p53 protein was found in 40 of 59 patients (67.8%) and that of mdm2 protein in 17 of 59 patients (28.8%). No obvious relationships were found between p53 as well as mdm2 expression and sex, tumor site, TNM staging and histological differentiation. p53 expression was increased in patients younger than 65 years old, while mdm2 had no relationship with age. The survival time of the patients with the positive expression of p53 and mdm2 proteins was obviously shorter than the other groups. CONCLUSION: Both p53 and mdm2 presented relatively high expression in humanpancreatic cancer. The overexpression of p53 and mdm2 might reflect the malignant proliferation of pancreatic cancer and their co-expression might be helpful to evaluate the prognosis of the patients with pancreatic cancer.
Authors: S Y Zhang; B Ruggeri; P Agarwal; A F Sorling; T Obara; H Ura; M Namiki; A J Klein-Szanto Journal: Arch Pathol Lab Med Date: 1994-02 Impact factor: 5.534
Authors: F A Sinicrope; D B Evans; S D Leach; K R Cleary; C J Fenoglio; J J Lee; J L Abbruzzese Journal: Clin Cancer Res Date: 1996-12 Impact factor: 12.531
Authors: Jan Franko; Alyssa M Krasinskas; Marina N Nikiforova; Narcis O Zarnescu; Kenneth K W Lee; Steven J Hughes; David L Bartlett; Herbert J Zeh; A James Moser Journal: J Gastrointest Surg Date: 2008-08-02 Impact factor: 3.452
Authors: Georgios Voidonikolas; Stephanie S Kreml; Changyi Chen; William E Fisher; F Charles Brunicardi; Richard A Gibbs; Marie-Claude Gingras Journal: World J Surg Date: 2009-04 Impact factor: 3.352
Authors: Jinyun Chen; Christopher I Amos; Kelly W Merriman; Qingyi Wei; Subrata Sen; Ann M Killary; Marsha L Frazier Journal: Pancreas Date: 2010-01 Impact factor: 3.327
Authors: Richard B Halberg; Xiaodi Chen; James M Amos-Landgraf; Alanna White; Kristin Rasmussen; Linda Clipson; Cheri Pasch; Ruth Sullivan; Henry C Pitot; William F Dove Journal: Genetics Date: 2008-08-24 Impact factor: 4.562